Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart.
Aging and diabetes mellitus (DM) both affect the structure and function of the myocardium, resulting in increased collagen in the heart and reduced cardiac function. As part of this process, hyperglycemia is a stimulus for the production of advanced glycation end products (AGEs), which covalently modify proteins and impair cell function. The goals of this study were first to examine the combined effects of aging and DM on hemodynamics and collagen types in the myocardium in 12 dogs, 9-12 yr old, and second to examine the effects of the AGE cross-link breaker phenyl-4,5-dimethylthazolium chloride (ALT-711) on myocardial collagen protein content, aortic stiffness, and left ventricular (LV) function in the aged diabetic heart. The alloxan model of DM was utilized to study the effects of DM on the aging heart. DM induced in the aging heart decreased LV systolic function (LV ejection fraction fell by 25%), increased aortic stiffness, and increased collagen type I and type III protein content. ALT-711 restored LV ejection fraction, reduced aortic stiffness and LV mass with no reduction in blood glucose level (199 +/- 17 mg/dl), and reversed the upregulation of collagen type I and type III. Myocardial LV collagen solubility (%) increased significantly after treatment with ALT-711. These data suggest that an AGE cross-link breaker may have a therapeutic role in aged patients with DM.
Liu
Jing
J
Department of Cell Biology and Molecular Medicine, and Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ 07101, USA.
Masurekar
Malthi R
MR
Vatner
Dorothy E
DE
Jyothirmayi
Garikiparthy N
GN
Regan
Timothy J
TJ
Vatner
Stephen F
SF
Meggs
Leonard G
LG
Malhotra
Ashwani
A
D000375:Aging / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose; D024042:Collagen Type I / Q000378:metabolism*; D024061:Collagen Type III / Q000378:metabolism*; D003432:Cross-Linking Reagents / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000378:metabolism; D004285:Dogs; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006439:Hemodynamics; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D012995:Solubility; D013844:Thiazoles / Q000494:pharmacology*
D001786:Blood Glucose; D024042:Collagen Type I; D024061:Collagen Type III; D003432:Cross-Linking Reagents; D017127:Glycation End Products, Advanced; D013844:Thiazoles; C406794:alagebrium